Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer

NCT07638631 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Locally Advanced Gastric Cancer

Interventions

DRUG: Ipilimumab injection N01
DRUG: Sintilimab
DRUG: Modified (60% standard dose) XELOX

Sponsor

Chen Lizhu